Please provide your email address to receive an email when new articles are posted on . Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an ...
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...
Please provide your email address to receive an email when new articles are posted on . NT-proBNP concentration is a strong predictor of ventricular arrhythmias among people with an implantable device ...
Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results